NCT06702995 2025-04-20Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerEvopoint Biosciences Inc.Phase 1/2 Recruiting307 enrolled
NCT02607228 2020-12-08Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate CancerGilead SciencesPhase 1/2 Terminated31 enrolled 22 charts